-- Conference Call Scheduled for
5:00 p.m. ET --
SAN
DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (EVFM) will hold an investor call as
follows:
|
Date:
|
Thursday, August
11, 2022
|
|
|
|
Time:
|
5:00 p.m. ET (2:00 p.m.
PT)
|
|
|
|
Live call:
|
(877)
445-9755 (U.S. toll-free)
or
(201) 493-6744
|
|
|
|
Webcast (live and
archived):
|
https://evofem.investorroom.com/Update or
https://www.webcast-eqs.com/register/evofem2022811/en
|
Please connect to the webcast at least 15 minutes prior to the
start of the call to download any software that may be required. If
participating by phone, please dial in approximately 15 minutes
prior to the start of the call.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(EVFM) is developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health,
including hormone-free, woman-controlled contraception and
protection from chlamydia and gonorrhea. The Company's first
FDA-approved product, Phexxi® (lactic acid, citric acid
and potassium bitartrate), is a hormone-free, on-demand
prescription contraceptive vaginal gel. It comes in a box of 12
pre-filled applicators and is applied 0-60 minutes before each act
of sex. The Company expects to report top-line data in October 2022 from its registrational Phase
3 EVOGUARD clinical trial evaluating Phexxi for two
potential new indications – prevention of chlamydia and prevention
of gonorrhea in women. Learn more
at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-host-investor-call-on-thursday-august-11-2022-301603911.html
SOURCE Evofem Biosciences, Inc.
